Cargando…
Soluble ST2 in end‐stage heart failure, before and after support with a left ventricular assist device
BACKGROUND: The interleukin‐33 (IL‐33)/suppressor of tumorigenicity 2 (ST2) pathway is suggested to play an important role in fibrosis, remodelling and the progression of heart failure (HF). Increased soluble (sST2) levels are associated with adverse outcome in the average HF population. Less is kno...
Autores principales: | Tseng, Cheyenne C. S., Huibers, Manon M. H., Gaykema, Lonneke H., Siera‐de Koning, Erica, Ramjankhan, Faiz Z., Maisel, Alan S., de Jonge, Nicolaas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838535/ https://www.ncbi.nlm.nih.gov/pubmed/29325227 http://dx.doi.org/10.1111/eci.12886 |
Ejemplares similares
-
Advanced Strategies for End-Stage Heart Failure: Combining Regenerative Approaches with LVAD, a New Horizon?
por: Tseng, Cheyenne C. S., et al.
Publicado: (2015) -
The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium
por: Tseng, Cheyenne C. S., et al.
Publicado: (2017) -
MicroRNA Expression in Myocardial Tissue and Plasma of Patients with End-Stage Heart Failure during LVAD Support: Comparison of Continuous and Pulsatile Devices
por: Lok, Sjoukje I., et al.
Publicado: (2015) -
Elevated Plasma Immunoglobulin Levels Prior to Heart Transplantation Are Associated with Poor Post-Transplantation Survival
por: van den Hoogen, Patricia, et al.
Publicado: (2022) -
Soluble ST2 Testing: A Promising Biomarker in the Management of
Heart Failure
por: Villacorta, Humberto, et al.
Publicado: (2016)